Mometasone Furoate nasal spray + Placebo

Phase 3Completed

0 watching 0 views this week📈 Rising

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Adenoids Hypertrophy

Conditions

Adenoids Hypertrophy

Trial Timeline

Aug 1, 2007 → Jan 1, 2010

NCT ID

NCT00552032

About Mometasone Furoate nasal spray + Placebo

Mometasone Furoate nasal spray + Placebo is a phase 3 stage product being developed by Organon for Adenoids Hypertrophy. The current trial status is completed. This product is registered under clinical trial identifier NCT00552032. Target conditions include Adenoids Hypertrophy.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (4)

NCT ID	Phase	Status	Start	Completion	Indication
NCT00552032	Phase 3	Completed	Aug 1, 2007	Jan 1, 2010	Adenoids Hypertrophy
NCT00468312	Phase 3	Completed	Mar 1, 2007	Jul 1, 2007	Seasonal Allergic Rhinitis
NCT00359216	Approved	Completed	May 1, 2006	Jan 1, 2008	Perennial Allergic Rhinitis
NCT00731185	Phase 3	Completed	Sep 1, 2003	Sep 1, 2005	Nasal Polyps

Competing Products

1 competing product in Adenoids Hypertrophy

See all competitors

Product	Company	Stage	Hype Score
mometasone furoate nasal spray	Organon	Approved	80

Other Products from Organon

desloratadineApproved

tibolone + raloxifenApproved

ezetimibe + statinsApproved

losartan potassium + Comparator: carvedilol + Comparator: losartan (+) hydrochlorothiazide (HCTZ) + Comparator: carvedilol (+) hydrochlorothiazideApproved

Desloratadine 5 mg + fexofenadineApproved